Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

LABA/LAMA fixed dose combinations in patients with COPD: a systematic review

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F.

January 2018

Objectives: To assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic ...

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS

Latorre, M
Novelli, F
Vagaggini, B
Braido, F
Papi, A
Santus, P
Scichilone, N
Paggiaro, P.
SANDUZZI ZAMPARELLI, ALESSANDRO

January 2015

Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often...

LABA/LAMA fixed dose combinations in patients with COPD: a systematic review

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F.

January 2018

Objectives: To assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic ...

Indacaterol/glycopyrronium or salmeterol/fluticasone for COPD exacerbations

Wedzicha, JA
Banerji, D
Chapman, KR
Vestbo, J
Roche, N
Ayers, T
Thach, C
Fogel, R
Patalano, F
Vogelmeier, CF
FLAME Investigators

March 2016

BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucoc...

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha, Jadwiga
Banerji, Donald
Chapman, Kenneth
Vestbo, Jorgen
Roche, Nicolas
Ayers, R Timothy
Thach, Chau
Fogel, Robert
Patalano, Francesco
Vogelmeier, Claus
Bourdin, Arnaud

June 2016

International audienceBACKGROUND:Most guidelines recommend either a long-acting beta-agonist (LABA) ...

Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD

Jadwiga, A.
Wedzicha, M. D.
Donald, Banerji
Kenneth R, M. D. .
Chapman, M. D.
Jørgen Vestbo, M. D.
Dmsc, D. M. S.c.
Nicolas Roche, M. D.
R. Timothy Ayers, M. S.c.
Chau, Thach
Phd, P.h. D.
Robert, Fogel
M. D. Francesco Patalano, M. D.
Claus F.
Vogelmeier, M. D.
for the FLAME, Investigators
FOSCHINO BARBARO, MARIA PIA

January 2016

BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled gluco...

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

Wedzicha, Jadwiga A
Banerji, Donald
Chapman, Kenneth R
Vestbo, Jørgen
Roche, Nicolas
Ayers, R Timothy
Thach, Chau
Fogel, Robert
Patalano, Francesco
Vogelmeier, Claus F

June 2016

Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or...

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Anzueto, AR
Kostikas, K
Mezzi, K
Shen, S
Larbig, M
Patalano, F
Fogel, R
Banerji, D
Wedzicha, JA

June 2018

Background Chronic obstructive pulmonary disease (COPD) is a progressive disease and a composite end...

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Vogelmeier, Claus F.
Gaga, Mina
Aalamian-Mattheis, Maryam
Greulich, Timm
Marin, Jose M.
Castellani, Walter
Ninane, Vincent
Lane, Stephen
Nunez, Xavier
Patalano, Francesco
Clemens, Andreas
Kostikas, Konstantinos

January 2017

Background: Dual bronchodilation combining a long-acting ß2-agonist (LABA) and a long-acting muscari...

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial

Frith, Peter A.
Ashmawi, Samiha
Krishnamurthy, Srikanth
Gurgun, Alev
Hristoskova, Sashka
Pilipovic, Virginia
Hamann, Anna Marie
Backer, Arthur
Olsson, Petter
Kostikas, Konstantinos
Diaz, Dina V.

January 2018

WOS: 000450142800014PubMed ID: 30074294Background and objective Combination long-acting beta(2)-agon...

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: a pooled analysis

Muro, S
Yoshisue, H
Kostikas, K
Olsson, P
Gupta, P
Wedzicha, JA

June 2019

BACKGROUND AND OBJECTIVE: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (q.d.) has demon...

LABA/LAMA fixed-dose combinations in patients with COPD : a systematic review

P. Rogliani
L. Calzetta
F. Braido
M. Cazzola
E. Clini
G. Pelaia
A. Rossi
N. Scichilone
F. Di Marco

October 2018

Objectives: The aim of this study was to assess the current evidence for long-acting \u3b22-agonist ...

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

Wedzicha, JA
Zhong, N
Ichinose, M
Humphries, M
Fogel, R
Thach, C
Patalano, F
Banerji, D

November 2016

Background: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY), the fixed-dose c...

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

Wedzicha JA
Zhong N
Ichinose M
Humphries M
Fogel R
Thach C
Patalano F
Banerji D

January 2017

Jadwiga A Wedzicha,1 Nanshan Zhong,2 Masakazu Ichinose,3 Michael Humphries,4 Robert Fogel,5 Chau Tha...

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F

January 2018

Objectives: The aim of this study was to assess the current evidence for long-acting \u3922-agonist ...

LABA/LAMA fixed dose combinations in patients with COPD: a systematic review

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F.

January 2018

Objectives: To assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic ...

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS

Latorre, M
Novelli, F
Vagaggini, B
Braido, F
Papi, A
Santus, P
Scichilone, N
Paggiaro, P.
SANDUZZI ZAMPARELLI, ALESSANDRO

January 2015

Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often...

LABA/LAMA fixed dose combinations in patients with COPD: a systematic review

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F.

January 2018

Objectives: To assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic ...

Indacaterol/glycopyrronium or salmeterol/fluticasone for COPD exacerbations

Wedzicha, JA
Banerji, D
Chapman, KR
Vestbo, J
Roche, N
Ayers, T
Thach, C
Fogel, R
Patalano, F
Vogelmeier, CF
FLAME Investigators

March 2016

BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucoc...

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha, Jadwiga
Banerji, Donald
Chapman, Kenneth
Vestbo, Jorgen
Roche, Nicolas
Ayers, R Timothy
Thach, Chau
Fogel, Robert
Patalano, Francesco
Vogelmeier, Claus
Bourdin, Arnaud

June 2016

International audienceBACKGROUND:Most guidelines recommend either a long-acting beta-agonist (LABA) ...

Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD

Jadwiga, A.
Wedzicha, M. D.
Donald, Banerji
Kenneth R, M. D. .
Chapman, M. D.
Jørgen Vestbo, M. D.
Dmsc, D. M. S.c.
Nicolas Roche, M. D.
R. Timothy Ayers, M. S.c.
Chau, Thach
Phd, P.h. D.
Robert, Fogel
M. D. Francesco Patalano, M. D.
Claus F.
Vogelmeier, M. D.
for the FLAME, Investigators
FOSCHINO BARBARO, MARIA PIA

January 2016

BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled gluco...

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

Wedzicha, Jadwiga A
Banerji, Donald
Chapman, Kenneth R
Vestbo, Jørgen
Roche, Nicolas
Ayers, R Timothy
Thach, Chau
Fogel, Robert
Patalano, Francesco
Vogelmeier, Claus F

June 2016

Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or...

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Anzueto, AR
Kostikas, K
Mezzi, K
Shen, S
Larbig, M
Patalano, F
Fogel, R
Banerji, D
Wedzicha, JA

June 2018

Background Chronic obstructive pulmonary disease (COPD) is a progressive disease and a composite end...

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Vogelmeier, Claus F.
Gaga, Mina
Aalamian-Mattheis, Maryam
Greulich, Timm
Marin, Jose M.
Castellani, Walter
Ninane, Vincent
Lane, Stephen
Nunez, Xavier
Patalano, Francesco
Clemens, Andreas
Kostikas, Konstantinos

January 2017

Background: Dual bronchodilation combining a long-acting ß2-agonist (LABA) and a long-acting muscari...

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial

Frith, Peter A.
Ashmawi, Samiha
Krishnamurthy, Srikanth
Gurgun, Alev
Hristoskova, Sashka
Pilipovic, Virginia
Hamann, Anna Marie
Backer, Arthur
Olsson, Petter
Kostikas, Konstantinos
Diaz, Dina V.

January 2018

WOS: 000450142800014PubMed ID: 30074294Background and objective Combination long-acting beta(2)-agon...

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: a pooled analysis

Muro, S
Yoshisue, H
Kostikas, K
Olsson, P
Gupta, P
Wedzicha, JA

June 2019

BACKGROUND AND OBJECTIVE: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (q.d.) has demon...

LABA/LAMA fixed-dose combinations in patients with COPD : a systematic review

P. Rogliani
L. Calzetta
F. Braido
M. Cazzola
E. Clini
G. Pelaia
A. Rossi
N. Scichilone
F. Di Marco

October 2018

Objectives: The aim of this study was to assess the current evidence for long-acting \u3b22-agonist ...

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

Wedzicha, JA
Zhong, N
Ichinose, M
Humphries, M
Fogel, R
Thach, C
Patalano, F
Banerji, D

November 2016

Background: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY), the fixed-dose c...

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

Wedzicha JA
Zhong N
Ichinose M
Humphries M
Fogel R
Thach C
Patalano F
Banerji D

January 2017

Jadwiga A Wedzicha,1 Nanshan Zhong,2 Masakazu Ichinose,3 Michael Humphries,4 Robert Fogel,5 Chau Tha...

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F

January 2018

Objectives: The aim of this study was to assess the current evidence for long-acting \u3922-agonist ...

LABA/LAMA fixed dose combinations in patients with COPD: a systematic review

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F.

January 2018

Objectives: To assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic ...

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS

Latorre, M
Novelli, F
Vagaggini, B
Braido, F
Papi, A
Santus, P
Scichilone, N
Paggiaro, P.
SANDUZZI ZAMPARELLI, ALESSANDRO

January 2015

Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often...

LABA/LAMA fixed dose combinations in patients with COPD: a systematic review

Rogliani, P
Calzetta, L
Braido, F
Cazzola, M
Clini, E
Pelaia, G
Rossi, A
Scichilone, N
Di Marco, F.

January 2018

Objectives: To assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic ...

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

Abstract

Extracted data

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

Abstract

Extracted data

Related items

Related items